KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Equity (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Return on Equity for 13 consecutive years, with 0.26% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 33.0% year-over-year to 0.26%, compared with a TTM value of 0.26% through Dec 2025, up 33.0%, and an annual FY2025 reading of 0.28%, up 29.0% over the prior year.
  • Return on Equity was 0.26% for Q4 2025 at Travere Therapeutics, up from 0.0% in the prior quarter.
  • Across five years, Return on Equity topped out at 5.32% in Q2 2024 and bottomed at 0.78% in Q3 2021.
  • Average Return on Equity over 5 years is 0.36%, with a median of 0.0% recorded in 2025.
  • The sharpest move saw Return on Equity surged 493bps in 2024, then plummeted -533bps in 2025.
  • Year by year, Return on Equity stood at 0.71% in 2021, then surged by 204bps to 0.74% in 2022, then soared by 49bps to 1.1% in 2023, then plummeted by -106bps to 0.06% in 2024, then surged by 510bps to 0.26% in 2025.
  • Business Quant data shows Return on Equity for TVTX at 0.26% in Q4 2025, 0.0% in Q3 2025, and 0.0% in Q2 2025.